Wave Life Sciences CEO Paul Bolno will speak at the Jefferies London Healthcare Conference on November 20, 2024.
Quiver AI Summary
Wave Life Sciences Ltd. announced that CEO Paul Bolno will participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2024. The event will be accessible via a live webcast on the company's Investor Relations website, with a replay available afterward. Wave Life Sciences, a clinical-stage biotechnology company based in Cambridge, MA, focuses on RNA medicines with its PRISM® platform, which employs various RNA-targeting modalities to address a range of diseases. The company is developing treatments for conditions such as Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and Huntington’s disease, and emphasizes its mission to transform health by unlocking the potential of RNA therapies.
Potential Positives
- Participation in the Jefferies London Healthcare Conference highlights the company's commitment to engaging with investors and analysts, showcasing its transparency and proactive communication strategy.
- The presence of the CEO at a prominent healthcare conference enhances Wave Life Sciences' visibility in the biotech sector, potentially attracting investor interest and increasing market awareness.
- The announcement reinforces Wave Life Sciences' focus on innovative RNA medicines, emphasizing its diverse pipeline and cutting-edge technology, which may bolster investor confidence in its growth potential.
- The archived replay of the presentation allows for continued engagement with stakeholders and provides an opportunity for broader audience reach beyond the live event.
Potential Negatives
- Participation in the fireside chat may indicate the company is seeking to boost investor confidence amidst persistent challenges in the biotechnology sector.
FAQ
When is Wave Life Sciences' upcoming event?
Wave Life Sciences will participate in the Jefferies London Healthcare Conference on November 20, 2024, at 4:30 p.m. GMT.
How can I watch the Wave Life Sciences presentation?
A live webcast of the presentation can be accessed on the Investor Relations section of the Wave Life Sciences website.
Who is presenting at the Jefferies London Healthcare Conference?
Paul Bolno, MD, MBA, the President and CEO of Wave Life Sciences, will be presenting at the event.
What is Wave Life Sciences focused on?
Wave Life Sciences is focused on developing RNA medicines to transform human health and address various diseases.
Where is Wave Life Sciences headquartered?
Wave Life Sciences is headquartered in Cambridge, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$WVE Insider Trading Activity
$WVE insiders have traded $WVE stock on the open market 9 times in the past 6 months. Of those trades, 1 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $WVE stock by insiders over the last 6 months:
- CHRIS FRANCIS (See Remarks) has traded it 5 times. They made 0 purchases and 5 sales, selling 244,836 shares.
- PAUL BOLNO (President and CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 138,840 shares.
- PLC GSK purchased 2,791,930 shares.
- KYLE MORAN (Chief Financial Officer) sold 17,146 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$WVE Hedge Fund Activity
We have seen 90 institutional investors add shares of $WVE stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRIEHAUS CAPITAL MANAGEMENT LLC added 4,950,764 shares (+545.2%) to their portfolio in Q3 2024
- ARTAL GROUP S.A. removed 4,566,251 shares (-100.0%) from their portfolio in Q3 2024
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 4,345,632 shares (+81.1%) to their portfolio in Q3 2024
- MAVERICK CAPITAL LTD added 2,378,159 shares (+31.0%) to their portfolio in Q3 2024
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,960,470 shares (+inf%) to their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. removed 1,859,259 shares (-94.2%) from their portfolio in Q2 2024
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,687,333 shares (+117.2%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET.
A live webcast of this presentation can be accessed by visiting “Investor Events” on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events . A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM
®
, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit
www.wavelifesciences.com
and follow Wave on
X
(formerly Twitter) and
LinkedIn
.
Investor Contact:
Kate Rausch
+1 617-949-4827
[email protected]
Media Contact:
Alicia Suter
+1 617-949-4817
[email protected]
